Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05412030 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 388
- Enrollment target
NCT05412030 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 388 participants.
The verdict
NCT05412030, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 388 participants
- Enrollment target
Study Summary
This is a Phase 2 clinical study to support the use of AFX3772 in healthy infants for the prevention of pneumococcal disease. The purpose of this study is to determine the safety, tolerability, and immunogenicity of 3 different formulations of AFX3772 compared with Prevnar 13 (PCV13) and Prevnar 20 (PCV). Part 1 is the dose escalation, lead-in portion of the study in which infants at each dose level will be randomized 3:1 in sequential cohorts of increasing doses of AFX3772 or PCV13. In Part 2, infants will be randomized to receive either one of two dose levels of AFX3772 or PCV20.
Interventions
- BIOLOGICAL Prevnar 13
- BIOLOGICAL AFX3772
- BIOLOGICAL Prevnar 20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 388 participants |
| Start Date | 2022-06-16 |
| Est. Completion | 2025-09-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05412030
The ClinicalTrials.gov registry entry for NCT05412030 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 388 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Prevnar 13 is the first listed.
NCT05412030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05412030 about?
NCT05412030 is a clinical study titled "A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants". This is a Phase 2 clinical study to support the use of AFX3772 in healthy infants for the prevention of pneumococcal disease. The purpose of this study is to determine the safety, tolerability, and immunogenicity of 3 different formulations of AFX3772 compared with Prevnar 13 (PCV13) and Prevnar 20 ...
What is the current status of trial NCT05412030?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 388 participants. The study started on 2022-06-16. Estimated completion is 2025-09-18.
What interventions are being tested in trial NCT05412030?
The interventions under investigation include: Prevnar 13 (BIOLOGICAL), AFX3772 (BIOLOGICAL), Prevnar 20 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05412030?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.